Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients.
OBJECTIVE
We investigated the immunoexpressions of cyclin D1, cyclin-dependent kinase inhibitor p16 and phosphorylated retinoblastoma (p-pRb) proteins in non-small cell lung carcinoma (NSCLC) to demonstrate their key roles in tumorigenesis, their relationship with the clinicopathologic factors, and their prognostic influences on the long-term survival.


METHODS
115 surgically resected NSCLCs were immunohistochemically stained for the G(1)/S cell cycle proteins, with using a tissue microarray. The correlation between their immunoexpressions and the clinicopathologic prognostic factors, their inter-relationships and their single or combined effects on the long-term survival (over 5 years) were statistically analyzed by SPSS15.0.


RESULTS
Loss of p16 was found in 75% of the cases and cyclin D1 overexpression and phosphorylated pRb (p-pRb) were found in 64% and 46%, respectively. Cyclin D1 overexpression was correlated with the p16 loss and pRb inactivation by phosphorylation. The p16 loss was tightly associated with p-pRb. The Kaplan-Meier survival curves disclosed that the cyclin D1-positive group and the p16-negative group showed a rapid decline of survival at the point of about 5 years after surgery and thereafter. The combined actions of cyclin D1 overexpression, loss of p16 and pRb inactivation tended to have an adverse influence on the prolonged survival.


CONCLUSIONS
The observation that cyclin D1 overexpression, p16 loss and pRb inactivation were largely found in NSCLCs suggests that they play an important role in pulmonary carcinogenesis. Also, their inverse or positive correlations indicate that the G(1)/S cell cycle proteins may act alternatively or synergistically on the mechanisms by which tumor cells escape the G(1) restriction point. Finally, their solitary or combined actions might have a long-term effect on the survival.
Myong
Na-Hye
NH
Department of Pathology, Dankook University College of Medicine, Cheonan, Korea. myongnh@dankook.ac.kr
Nature. 1993 Dec 16;366(6456):704-7
8259215
Clin Cancer Res. 2005 Jun 1;11(11):3974-86
15930332
Br J Cancer. 1997;75(12):1761-8
9192978
Cancer Res. 1995 Feb 1;55(3):505-9
7834618
Int J Cancer. 1997 Oct 21;74(5):556-62
9355981
Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7827-31
8052667
Carcinogenesis. 2002 Jul;23(7):1217-27
12117781
Cancer Res. 1996 Aug 1;56(15):3415-20
8758904
Br J Cancer. 1996 Feb;73(3):294-300
8562333
J Clin Pathol. 2004 Jan;57(1):58-63
14693837
J Pathol. 1999 Aug;188(4):341-3
10440742
Clin Cancer Res. 2005 Jan 1;11(1):232-41
15671551
Mod Pathol. 2005 Apr;18(4):565-72
15502804
Science. 1996 Dec 6;274(5293):1672-7
8939849
Int J Cancer. 1998 Jan 19;75(2):187-92
9462706
Int J Cancer. 1996 Feb 8;65(4):442-5
8621224
Cancer Res. 1995 Nov 1;55(21):4818-23
7585513
Cancer. 2007 Jun 15;109(12):2506-14
17487846
EMBO J. 1996 Dec 16;15(24):7060-9
9003781
Lung Cancer. 2001 Apr;32(1):27-38
11282426
Lung Cancer. 2003 Dec;42(3):275-81
14644514
Br J Cancer. 2000 Jan;82(2):374-80
10646891
J Pathol. 1999 Aug;188(4):351-60
10440744
Oncogene. 2002 Oct 7;21(45):6908-14
12362273
Cancer Res. 1999 May 15;59(10):2470-6
10344760